Ciltacabtagene autoleucel (cilta-cel) https://ash./ash/2020/webprogram/Paper136307.html ASh19和ASCO20展示了Ph1b中29例pts的结果,这次还加上了Ph2部分的68例合计97例,截止到2020年5月20日,随访中位时间8.8mo 患者中位年龄61[range 43–78],先前接受治疗的线程中位数6(range 3–18);,83.5%接受过5药治疗,87.6%三重难治,41.2%五重难治。 疗效
安全性方面
安全性
疗效
CT053在北美RRMM中的Lummicar-2结果(Ph1b/2,NCT03915184) https://ash./ash/2020/webprogram/Paper139802.html 截止到2020年7月28日,共入组20例患者,14例在Ph1b部分——包括8例1.5-1.8×10^8 CAR+ T cells剂量和6 例2.5-3.0×10^8 CAR+ T cells 基线:
安全性:
疗效
最后就是CT053的IIT研究2年随访(NCT03716856, NCT03302403, and NCT03380039) https://ash./ash/2020/webprogram/Session19607.html 24例患者,中位年龄60.1,先前治疗线程中位数4.5,41.7%接受过ASCT 截止至2020年6月30日,9例患者完成了24mo的随访,包括8例sCR和1例CR,未能完成随访的15例患者中13例因为PD,2例因为接受其他治疗 整体ORR 87.5%,其中sCR/CR 79.2%;DoR 21.8mo,PFS 18.8mo,6mo及12mo PFS分别87%和60.9% 13例进展的患者的mPFS 10.2mo,相比于剩下9例持续sCR/CR的患者,这13例患者有着更高比例的ECOG 2-3分、ISS Gr III和高危细胞遗传学 CRS通常发生在Day 1-4,一般6d就可以恢复:62.5%(15/24)的患者报道有低级CRS,均在2-8d内恢复。有1例患者经历了Gr3的神经毒性并且伴随Gr2 的CRS,该患者在接受甲强龙、地西泮和丙戊酸钠治疗后3d恢复 BCMA-CD19-directed FasT CAR-T (GC012F) https://ash./ash/2020/webprogram/Paper138614.html 截止至2020-7-17,共入组16例患者,3个剂量水平/DL: 1x10^5/Kg (DL1) (1 patients)、2x10^5/Kg (DL2) (9 patients) 、3x10^5/Kg (DL3) (6 patients) ORR 93.8%(15/16),最佳缓解为MRD- CR/sCR的占 56.3%(9/16) DL3下 100% (6/6) 获得sCR, 其中3例在数据截止日经PET-CT确认 所有可评估缓解的患者中,78.6% (11/14) 、100%(11/11)和100%(10/10)的第1、3和6个月确认MRD- :7例和9例在10^-4和10^-6敏感度水平 In all response evaluable patients, 78.6% (11/14) were MRD- by flow at month 1, and 100% at month 3 (11/11) and 6 (10/10) (sensitivity by flow cytometry measured at 10-4 in 7 patients, and at 10-6 in 9 patients tested by EuroFlow with at least 1.08x107 cells analyzed). 随访时间中位值7.3mo,最长的10mo At data cut off, the median follow up time was 7.3 months, the longest follow up was 10 months post infusion. CAR-T PK in PB was monitored by qPCR and flow cytometry. The CAR-T median proliferation peak was reached on Day10 (Day8-Day14), and the median peak copy number was 140,982 (16,011-374,346) copies /ug DNA. 安全谱可接受,Gr 1-2的 CRS占87.5%,Gr 3-4的 CRS占12.5%,一般持续4d GC012F showed an acceptable safety profile with 14 out of 16 patients experiencing a cytokine release syndrome (CRS) grade 1-2 (n=14, 87.5%) and 2 grade 3 (n=2, 12.5%). The median duration of CRS was 4 days (1-8 days). 没有报道NT No neurotoxicity of any grade was observed. One patient (DL2) presented with fever and died shortly after Day 78 of unknown cause during the COVID-19 Pandemic. Two patients had progression of extramedullary disease while achieving MRD negativity at month 1 and 3, respectively. At landmark analysis at 6 months, all patients in DL3 had achieved and maintained MRD- sCR including patients heavily pretreated including Daratumumab – among them 83.3% (5/6) patients in DL3 had high risk features according to mSMART criteria, and 5 out of 6 patients in DL3 were assessed by 10-6 Euroflow for MRD. The study is still enrolling patients and we will continue to be monitoring safety and efficacy including duration of response. 实在来不及更了 |
|